Medtronic, Minneapolis, Minnesota) with radiofrequency (RF) ablation. In total, 322 patients with symptomatic paroxysmal atrial fibrillation (AF) were randomly assigned to either strategy for pulmonary vein isolation. Freedom from AF at the 12-month mark was comparable between the 2 arms (CB, 68% vs. RF, 65%), with a similar adverse event profile except for phrenic nerve injury, which was higher in the CB group. In another study, the HeartLight Trial demonstrated that, in terms of safety and efficacy, the laser balloon too was noninferior to RF ablation. This study examined the ability to perform pulmonary vein isolation using the HeartLight system (CardioFocus, Marlborough, Massachusetts), compared with a control arm using an irrigated RF ablation catheter 
ATRIAL FIBRILLATION
Catheter ablation continued to remain center stage, with 2 important studies at the HRS meeting in Boston, Massachusetts, examining balloon-based technology with alternative energy sources. The FreezeAF study, a prospective, randomized, controlled, noninferiority study compared the safety and effectiveness of a cryoballoon (CB) ablation catheter (Arctic Front, Medtronic, Minneapolis, Minnesota) with radiofrequency (RF) ablation. In total, 322 patients with symptomatic paroxysmal atrial fibrillation (AF) were randomly assigned to either strategy for pulmonary vein isolation. Freedom from AF at the 12-month mark was comparable between the 2 arms (CB, 68% vs. RF, 65%), with a similar adverse event profile except for phrenic nerve injury, which was higher in the CB group. In another study, the HeartLight Trial demonstrated that, in terms of safety and efficacy, the laser balloon too was noninferior to RF ablation. This study examined the ability to perform pulmonary vein isolation using the HeartLight system (CardioFocus, Marlborough, Massachusetts), compared with a control arm using an irrigated RF ablation catheter Over the past few years, the failings of transvenous pacing systems have been repeatedly emphasized.
The consequent attempt to eliminate the subcutaneous generator and the lead system with miniaturized leadless pacemakers seems to be becoming a reality. All of the pacing and sensing parameters remained optimal throughout the follow-up. Of course, a longer follow-up will be of interest to assess the durability of these findings and the concern about the retrieval or subsequent additional device implantation when it is considered.
Another presentation explored the role of leadless pacing of the LV. The SELECT-LV trial is a prospective, nonrandomized study using a wireless and leadless endocardial LV pacing system (Wise LV, EBR Systems, Sunnyvale, California) to achieve cardiac resynchronization. This system uses a subcutaneous generator that transmits ultrasound energy to an LV pacing-pellet, which converts this into pacing output.
Patients (n ¼ 39) with a wide QRS who had failed conventional cardiac resynchronization therapy (CRT) were recruited. The procedure involves the implantation of a subcutaneous battery and transmitter followed by a transvascular procedure to place the endocardial pacing pellet. This device is then able to synchronize LV pacing to the right ventricular pacing impulse from other pacing devices. Although
Guest Editor's Page
A U G U S T 2 0 1 5 : 3 3 7 -9 previous data from the published WISE-CRT study had shown cardiac perforation to be a problem (6), this was not observed in the SELECT-LV study. 
